FGEN FibroGen
- 1.030
- -0.030-2.83%
FibroGen News
Favourable Signals For FibroGen: Numerous Insiders Acquired Stock
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To
FibroGen(FGEN.US) Officer Buys US$25,883.91 in Common Stock
$FibroGen(FGEN.US)$ Officer Adib Deyaa purchased 22,123 shares of common stock on Jun 12, 2024 at an average price of $1.17 for a total value of $25,883.91.Source: Announcement What is statement of ch
Pancreatic Cancer on the Rise: How Biotech Firms Are Developing Groundbreaking Treatments
After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may ...
What's Going On With FibroGen Stock Tuesday?
FibroGen Inc (NASDAQ:FGEN) shares initially traded higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical t
Top Premarket Gainers
MicroAlgo (MLGO) shares were up more than 160% premarket Tuesday amid a collaboration with WiMi Hologram Cloud (WIMI) to jointly set up a micro-consciousness quantum research center. Core Scientific (
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Healthequity Inc (NASDAQ:HQY) rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results.The company reported quarterly earnings
FibroGen Stock Rallies 30% After Hours on FG-3165, FG-3175 Updates
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier
FibroGen (FGEN) was up 26% in recent after-hours activity Monday after the US Food and Drug Administration accepted its investigational new drug application for FG-3165 to treat solid tumors character
FibroGen Stock Is Surging After The Bell: What's Going On?
FibroGen Inc (NASDAQ:FGEN) shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) for FG-3165. The company also announc
12 Health Care Stocks Moving In Monday's After-Market Session
GainersFibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ
FibroGen To Begin Trials on Tumor Treatment After FDA OK
By Ben Glickman FibroGen can begin conducting clinical trials for its potential solid tumor treatment after regulators approved the company's application. The San Francisco-based company said Monday
Express News | FibroGen Inc -Both FG-3165 and FG-3175 Have Demonstrated Complementary Mechanisms of Action With Pd-1 Inhibitors in Preclinical Studies
FibroGen Announces Clinical Trial Supply Agreement With Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (Anti-Galectin 9) and FG-3175 (Anti-CCR8), in Combination With LIBTAYO in Upcoming Clinical Trials
FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen's immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron's anti-PD-1 therapy, LIBTAYO (cemiplimab), in patients with solid tumors.
Express News | FibroGen Announces Clinical Trial Supply Agreement With Regeneron Pharmaceuticals to Evaluate Fibrogen’s Immuno-Oncology Assets, FG-3165 (Anti-Galectin 9) and FG-3175 (Anti-Ccr8), in Combination With Libtayo® in Upcoming Clinical Trials
Express News | FibroGen Inc - Safety and Efficacy of FG-3165 Will Be Evaluated in a Phase 1 Trial in Select Solid Tumors
Express News | FibroGen Inc - Plan to Begin Enrollment in 2H 2024
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients With Solid Tumors
FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression.
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs 45th A
Analysis
Price Target
No Data
